J&J paying $2.2bn in 'shameful' fraud case
This article was originally published in Scrip
Executive Summary
Johnson & Johnson and its subsidiaries found out the hard way the FDA is dead serious when it warns drug makers that ignore the agency's regulatory authority they are doing so at their own peril.